Interleukin-2 and regulatory T cells in graft-versus-host disease

John Koreth, Ken-ichi Matsuoka, Haesook T. Kim, Sean M. McDonough, Bhavjot Bindra, Edwin P. Alyea, Philippe Armand, Corey Cutler, Vincent T. Ho, Nathaniel S. Treister, Don C. Bienfang, Sashank Prasad, Dmitrios Tzachanis, Robin M. Joyce, David E. Avigan, Joseph H. Antin, Jerome Ritz, Robert J. Soiffer

Research output: Contribution to journalArticle

587 Citations (Scopus)

Abstract

BACKGROUND: Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. METHODS: In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×10 6, 1×10 6, or 3×10 6 IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS: A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×106 IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P

Original languageEnglish
Pages (from-to)2055-2066
Number of pages12
JournalNew England Journal of Medicine
Volume365
Issue number22
Publication statusPublished - Dec 1 2011
Externally publishedYes

Fingerprint

Graft vs Host Disease
Regulatory T-Lymphocytes
Interleukin-2
Maximum Tolerated Dose
Body Surface Area
Glucocorticoids
Observational Studies
Cell Survival
Cohort Studies
Safety
Recurrence
Growth
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Koreth, J., Matsuoka, K., Kim, H. T., McDonough, S. M., Bindra, B., Alyea, E. P., ... Soiffer, R. J. (2011). Interleukin-2 and regulatory T cells in graft-versus-host disease. New England Journal of Medicine, 365(22), 2055-2066.

Interleukin-2 and regulatory T cells in graft-versus-host disease. / Koreth, John; Matsuoka, Ken-ichi; Kim, Haesook T.; McDonough, Sean M.; Bindra, Bhavjot; Alyea, Edwin P.; Armand, Philippe; Cutler, Corey; Ho, Vincent T.; Treister, Nathaniel S.; Bienfang, Don C.; Prasad, Sashank; Tzachanis, Dmitrios; Joyce, Robin M.; Avigan, David E.; Antin, Joseph H.; Ritz, Jerome; Soiffer, Robert J.

In: New England Journal of Medicine, Vol. 365, No. 22, 01.12.2011, p. 2055-2066.

Research output: Contribution to journalArticle

Koreth, J, Matsuoka, K, Kim, HT, McDonough, SM, Bindra, B, Alyea, EP, Armand, P, Cutler, C, Ho, VT, Treister, NS, Bienfang, DC, Prasad, S, Tzachanis, D, Joyce, RM, Avigan, DE, Antin, JH, Ritz, J & Soiffer, RJ 2011, 'Interleukin-2 and regulatory T cells in graft-versus-host disease', New England Journal of Medicine, vol. 365, no. 22, pp. 2055-2066.
Koreth J, Matsuoka K, Kim HT, McDonough SM, Bindra B, Alyea EP et al. Interleukin-2 and regulatory T cells in graft-versus-host disease. New England Journal of Medicine. 2011 Dec 1;365(22):2055-2066.
Koreth, John ; Matsuoka, Ken-ichi ; Kim, Haesook T. ; McDonough, Sean M. ; Bindra, Bhavjot ; Alyea, Edwin P. ; Armand, Philippe ; Cutler, Corey ; Ho, Vincent T. ; Treister, Nathaniel S. ; Bienfang, Don C. ; Prasad, Sashank ; Tzachanis, Dmitrios ; Joyce, Robin M. ; Avigan, David E. ; Antin, Joseph H. ; Ritz, Jerome ; Soiffer, Robert J. / Interleukin-2 and regulatory T cells in graft-versus-host disease. In: New England Journal of Medicine. 2011 ; Vol. 365, No. 22. pp. 2055-2066.
@article{07858626eca844b7ba90296123329566,
title = "Interleukin-2 and regulatory T cells in graft-versus-host disease",
abstract = "BACKGROUND: Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. METHODS: In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×10 6, 1×10 6, or 3×10 6 IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS: A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×106 IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P",
author = "John Koreth and Ken-ichi Matsuoka and Kim, {Haesook T.} and McDonough, {Sean M.} and Bhavjot Bindra and Alyea, {Edwin P.} and Philippe Armand and Corey Cutler and Ho, {Vincent T.} and Treister, {Nathaniel S.} and Bienfang, {Don C.} and Sashank Prasad and Dmitrios Tzachanis and Joyce, {Robin M.} and Avigan, {David E.} and Antin, {Joseph H.} and Jerome Ritz and Soiffer, {Robert J.}",
year = "2011",
month = "12",
day = "1",
language = "English",
volume = "365",
pages = "2055--2066",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "22",

}

TY - JOUR

T1 - Interleukin-2 and regulatory T cells in graft-versus-host disease

AU - Koreth, John

AU - Matsuoka, Ken-ichi

AU - Kim, Haesook T.

AU - McDonough, Sean M.

AU - Bindra, Bhavjot

AU - Alyea, Edwin P.

AU - Armand, Philippe

AU - Cutler, Corey

AU - Ho, Vincent T.

AU - Treister, Nathaniel S.

AU - Bienfang, Don C.

AU - Prasad, Sashank

AU - Tzachanis, Dmitrios

AU - Joyce, Robin M.

AU - Avigan, David E.

AU - Antin, Joseph H.

AU - Ritz, Jerome

AU - Soiffer, Robert J.

PY - 2011/12/1

Y1 - 2011/12/1

N2 - BACKGROUND: Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. METHODS: In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×10 6, 1×10 6, or 3×10 6 IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS: A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×106 IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P

AB - BACKGROUND: Dysfunction of regulatory T (Treg) cells has been detected in diverse inflammatory disorders, including chronic graft-versus-host disease (GVHD). Interleukin-2 is critical for Treg cell growth, survival, and activity. We hypothesized that low-dose interleukin-2 could preferentially enhance Treg cells in vivo and suppress clinical manifestations of chronic GVHD. METHODS: In this observational cohort study, patients with chronic GVHD that was refractory to glucocorticoid therapy received daily low-dose subcutaneous interleukin-2 (0.3×10 6, 1×10 6, or 3×10 6 IU per square meter of body-surface area) for 8 weeks. The end points were safety and clinical and immunologic response. After a 4-week hiatus, patients with a response could receive interleukin-2 for an extended period. RESULTS: A total of 29 patients were enrolled. None had progression of chronic GVHD or relapse of a hematologic cancer. The maximum tolerated dose of interleukin-2 was 1×106 IU per square meter. The highest dose level induced unacceptable constitutional symptoms. Of the 23 patients who could be evaluated for response, 12 had major responses involving multiple sites. The numbers of CD4+ Treg cells were preferentially increased in all patients, with a peak median value, at 4 weeks, that was more than eight times the baseline value (P

UR - http://www.scopus.com/inward/record.url?scp=82555168440&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=82555168440&partnerID=8YFLogxK

M3 - Article

C2 - 22129252

AN - SCOPUS:82555168440

VL - 365

SP - 2055

EP - 2066

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 22

ER -